Mallinckrodt PLC (MNK) Receives Average Recommendation of “Buy” from Analysts
Mallinckrodt PLC (NYSE:MNK) has received an average recommendation of “Buy” from the nineteen brokerages that are presently covering the stock. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and fifteen have given a buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $91.52.
A number of research firms have weighed in on MNK. Zacks Investment Research downgraded Mallinckrodt PLC from a “hold” rating to a “sell” rating in a report on Tuesday, October 4th. Goldman Sachs Group Inc. reissued a “neutral” rating and issued a $83.00 target price on shares of Mallinckrodt PLC in a report on Friday, August 26th. Vetr raised Mallinckrodt PLC from a “hold” rating to a “buy” rating and set a $88.80 target price on the stock in a report on Monday, August 22nd. Barclays PLC reissued an “overweight” rating and issued a $88.00 target price on shares of Mallinckrodt PLC in a report on Thursday, August 25th. Finally, Mizuho lowered their target price on Mallinckrodt PLC from $91.00 to $89.00 and set a “buy” rating on the stock in a report on Thursday, September 29th.
Shares of Mallinckrodt PLC (NYSE:MNK) opened at 65.82 on Tuesday. The company has a market cap of $7.09 billion, a P/E ratio of 12.41 and a beta of 1.53. Mallinckrodt PLC has a 12 month low of $50.90 and a 12 month high of $85.83. The stock’s 50 day moving average price is $72.56 and its 200-day moving average price is $66.77.
Mallinckrodt PLC (NYSE:MNK) last announced its quarterly earnings results on Tuesday, August 2nd. The company reported $2.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.00 by $0.20. The firm had revenue of $970.60 million for the quarter, compared to the consensus estimate of $920.35 million. Mallinckrodt PLC had a return on equity of 17.78% and a net margin of 16.39%. The company’s quarterly revenue was up .6% on a year-over-year basis. During the same period in the prior year, the company posted $2.05 earnings per share. Equities research analysts expect that Mallinckrodt PLC will post $7.63 earnings per share for the current year.
A number of institutional investors have recently made changes to their positions in the stock. Laurel Wealth Advisors Inc. raised its position in shares of Mallinckrodt PLC by 0.5% in the second quarter. Laurel Wealth Advisors Inc. now owns 3,427 shares of the company’s stock worth $208,000 after buying an additional 16 shares during the last quarter. Turner Investments L.P. raised its position in shares of Mallinckrodt PLC by 0.5% in the second quarter. Turner Investments L.P. now owns 19,420 shares of the company’s stock worth $1,180,000 after buying an additional 100 shares during the last quarter. Investors Capital Advisory Services raised its position in shares of Mallinckrodt PLC by 1.2% in the second quarter. Investors Capital Advisory Services now owns 8,710 shares of the company’s stock worth $529,000 after buying an additional 107 shares during the last quarter. LS Investment Advisors LLC raised its stake in Mallinckrodt PLC by 2.4% in the second quarter. LS Investment Advisors LLC now owns 5,408 shares of the company’s stock valued at $329,000 after buying an additional 126 shares during the last quarter. Finally, Aviva PLC raised its stake in Mallinckrodt PLC by 0.5% in the first quarter. Aviva PLC now owns 63,433 shares of the company’s stock valued at $3,887,000 after buying an additional 322 shares during the last quarter. 94.74% of the stock is owned by institutional investors.
Mallinckrodt PLC Company Profile
Mallinckrodt public limited company (Mallinckrodt) is engaged in the specialty pharmaceuticals and nuclear imaging business. The Company develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products, and nuclear imaging agents. The Company’s segments include Specialty Brands, Specialty Generics and Nuclear Imaging.
Receive News & Ratings for Mallinckrodt PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt PLC and related companies with MarketBeat.com's FREE daily email newsletter.